Effects of stenting for atherosclerotic renal artery stenosis on eGFR and predictors of clinical events in the CORAL trial

Katherine R. Tuttle; Lance D. Dworkin; William Henrich; Barbara A. Greco; Michael Steffes; Sheldon Tobe; Joseph I. Shapiro; Kenneth Jamerson; Asya Lyass; Karol Pencina; Joseph M. Massaro; Ralph B. D’Agostino; Donald E. Cutlip; Timothy P. Murphy; Christopher J. Cooper

doi:10.2215/CJN.10491015

Effects of stenting for atherosclerotic renal artery stenosis on eGFR and predictors of clinical events in the CORAL trial

Katherine R. Tuttle, Lance D. Dworkin, William Henrich, Barbara A. Greco, Michael Steffes, Sheldon Tobe, Joseph I. Shapiro, Kenneth Jamerson, Asya Lyass, Karol Pencina, Joseph M. Massaro, Ralph B. D’Agostino, Donald E. Cutlip, Timothy P. Murphy, Christopher J. Cooper

Laboratory Medicine and Pathology

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Abstract

Background and objectives Atherosclerotic renal artery stenosis may cause kidney function loss, but effects of stenting on eGFR and clinical events associated with CKD are uncertain. Our study objectives were to determine effects of stenting on eGFR and predictors of clinical events. Design, setting, participants, & measurements: Participants (n=931) in the Cardiovascular Outcomes in Renal Artery Stenosis Trial (fromMay of 2005 to September of 2012) had >60% atherosclerotic renal artery stenosis and systolic hypertension on two or more antihypertensive drugs and/or stage >3 CKD. The intervention was stenting versus no stenting on a background of risk factor management: renin-angiotensin system inhibition, statin, antiplatelet therapy, and smoking cessation education. The effect of stenting on eGFR by the serum creatinine-cystatin C Chronic Kidney Disease Epidemiology Collaboration equation was the prespecified analysis of kidney function. Predictors of eGFR and CKD outcomes (>30% eGFR loss, ESRD, and death) and cardiovascular disease outcomes (stroke, myocardial infarction, heart failure, and death) controlling for eGFR and albuminuria were also determined. Results: eGFR was 59±24 ml/min per 1.73 m² (mean±SD) at baseline. Over 3 years, eGFR change, assessed by generalized estimating equations, was-1.5±7.0ml/min per 1.73m² per year in the stent group versus-2.3±6.3 ml/min per 1.73 m² per year in the medical therapy only group (P=0.18). eGFR predictors (multiple variable generalized estimating equations) were age, albuminuria, systolic BP, and diabetes (inverse associations) as well as men, total cholesterol, andHDL cholesterol (positive associations). CKDoutcomes events occurred in 19%(175 of 931), and predictors (Cox proportional hazards models) included albuminuria (positive association), systolic BP (positive association), and HDL cholesterol (inverse association). Cardiovascular disease outcomes events occurred in 22% (207 of 931), and predictors included age, albuminuria, total cholesterol, prior cardiovascular disease, and bilateral atherosclerotic renal artery stenosis (positive associations). Conclusions: Stenting did not influence eGFR in participants with atherosclerotic renal artery stenosis receiving renin-angiotensin system inhibition-based therapy. Predictors of clinical events were traditional risk factors for CKD and cardiovascular disease.

Original language	English (US)
Pages (from-to)	1180-1188
Number of pages	9
Journal	Clinical Journal of the American Society of Nephrology
Volume	11
Issue number	7
DOIs	https://doi.org/10.2215/CJN.10491015
State	Published - 2016

Bibliographical note

Funding Information:
The authors appreciate the support and encouragement provided by Diane M. Reid (Medical Officer, Division of Cardiovascular Sciences, National Heart, Lung and Blood Institute [NHLBI], Bethesda, MD). The Cardiovascular Outcomes in Renal Artery Stenosis Clinical Trial was supported by NHLBI of the National Institutes of Health grants U01HL071556, U01HL072734, U01HL072735, U01HL072736, and U01HL072737. Study drugs were provided by Astra Zeneca and Pfizer Inc. Study devices were provided by Cordis Corporation, and supplemental financial support was granted by both Cordis Corporation and Pfizer Inc. None of the sponsors had roles in design andconduct of the study; collection, management, analysis, and interpretation of the data; or review or approval of the manuscript. The content of this paper is solely the responsibility of the authors.

Publisher Copyright:
© 2016 by the American Society of Nephrology.

Keywords

Albuminuria
Blood pressure
Cardiovascular disease
Chronic kidney disease
Glomerular filtration rate
Hypertension
Renal Artery Obstruction
Renin angiotensin system
Stents

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.2215/CJN.10491015

OpenUrl availability

Full text

Cite this

Tuttle, K. R., Dworkin, L. D., Henrich, W., Greco, B. A., Steffes, M., Tobe, S., Shapiro, J. I., Jamerson, K., Lyass, A., Pencina, K., Massaro, J. M., D’Agostino, R. B., Cutlip, D. E., Murphy, T. P., & Cooper, C. J. (2016). Effects of stenting for atherosclerotic renal artery stenosis on eGFR and predictors of clinical events in the CORAL trial. Clinical Journal of the American Society of Nephrology, 11(7), 1180-1188. https://doi.org/10.2215/CJN.10491015

Tuttle, KR, Dworkin, LD, Henrich, W, Greco, BA, Steffes, M, Tobe, S, Shapiro, JI, Jamerson, K, Lyass, A, Pencina, K, Massaro, JM, D’Agostino, RB, Cutlip, DE, Murphy, TP & Cooper, CJ 2016, 'Effects of stenting for atherosclerotic renal artery stenosis on eGFR and predictors of clinical events in the CORAL trial', Clinical Journal of the American Society of Nephrology, vol. 11, no. 7, pp. 1180-1188. https://doi.org/10.2215/CJN.10491015

@article{044f7561a4064ec096abcdef6aade5a4,

title = "Effects of stenting for atherosclerotic renal artery stenosis on eGFR and predictors of clinical events in the CORAL trial",

abstract = "Background and objectives Atherosclerotic renal artery stenosis may cause kidney function loss, but effects of stenting on eGFR and clinical events associated with CKD are uncertain. Our study objectives were to determine effects of stenting on eGFR and predictors of clinical events. Design, setting, participants, & measurements: Participants (n=931) in the Cardiovascular Outcomes in Renal Artery Stenosis Trial (fromMay of 2005 to September of 2012) had >60% atherosclerotic renal artery stenosis and systolic hypertension on two or more antihypertensive drugs and/or stage >3 CKD. The intervention was stenting versus no stenting on a background of risk factor management: renin-angiotensin system inhibition, statin, antiplatelet therapy, and smoking cessation education. The effect of stenting on eGFR by the serum creatinine-cystatin C Chronic Kidney Disease Epidemiology Collaboration equation was the prespecified analysis of kidney function. Predictors of eGFR and CKD outcomes (>30% eGFR loss, ESRD, and death) and cardiovascular disease outcomes (stroke, myocardial infarction, heart failure, and death) controlling for eGFR and albuminuria were also determined. Results: eGFR was 59±24 ml/min per 1.73 m2 (mean±SD) at baseline. Over 3 years, eGFR change, assessed by generalized estimating equations, was-1.5±7.0ml/min per 1.73m2 per year in the stent group versus-2.3±6.3 ml/min per 1.73 m2 per year in the medical therapy only group (P=0.18). eGFR predictors (multiple variable generalized estimating equations) were age, albuminuria, systolic BP, and diabetes (inverse associations) as well as men, total cholesterol, andHDL cholesterol (positive associations). CKDoutcomes events occurred in 19%(175 of 931), and predictors (Cox proportional hazards models) included albuminuria (positive association), systolic BP (positive association), and HDL cholesterol (inverse association). Cardiovascular disease outcomes events occurred in 22% (207 of 931), and predictors included age, albuminuria, total cholesterol, prior cardiovascular disease, and bilateral atherosclerotic renal artery stenosis (positive associations). Conclusions: Stenting did not influence eGFR in participants with atherosclerotic renal artery stenosis receiving renin-angiotensin system inhibition-based therapy. Predictors of clinical events were traditional risk factors for CKD and cardiovascular disease.",

keywords = "Albuminuria, Blood pressure, Cardiovascular disease, Chronic kidney disease, Glomerular filtration rate, Hypertension, Renal Artery Obstruction, Renin angiotensin system, Stents",

author = "Tuttle, {Katherine R.} and Dworkin, {Lance D.} and William Henrich and Greco, {Barbara A.} and Michael Steffes and Sheldon Tobe and Shapiro, {Joseph I.} and Kenneth Jamerson and Asya Lyass and Karol Pencina and Massaro, {Joseph M.} and D{\textquoteright}Agostino, {Ralph B.} and Cutlip, {Donald E.} and Murphy, {Timothy P.} and Cooper, {Christopher J.}",

note = "Funding Information: The authors appreciate the support and encouragement provided by Diane M. Reid (Medical Officer, Division of Cardiovascular Sciences, National Heart, Lung and Blood Institute [NHLBI], Bethesda, MD). The Cardiovascular Outcomes in Renal Artery Stenosis Clinical Trial was supported by NHLBI of the National Institutes of Health grants U01HL071556, U01HL072734, U01HL072735, U01HL072736, and U01HL072737. Study drugs were provided by Astra Zeneca and Pfizer Inc. Study devices were provided by Cordis Corporation, and supplemental financial support was granted by both Cordis Corporation and Pfizer Inc. None of the sponsors had roles in design andconduct of the study; collection, management, analysis, and interpretation of the data; or review or approval of the manuscript. The content of this paper is solely the responsibility of the authors. Publisher Copyright: {\textcopyright} 2016 by the American Society of Nephrology.",

year = "2016",

doi = "10.2215/CJN.10491015",

language = "English (US)",

volume = "11",

pages = "1180--1188",

journal = "Clinical Journal of the American Society of Nephrology",

issn = "1555-9041",

publisher = "American Society of Nephrology",

number = "7",

}

TY - JOUR

T1 - Effects of stenting for atherosclerotic renal artery stenosis on eGFR and predictors of clinical events in the CORAL trial

AU - Tuttle, Katherine R.

AU - Dworkin, Lance D.

AU - Henrich, William

AU - Greco, Barbara A.

AU - Steffes, Michael

AU - Tobe, Sheldon

AU - Shapiro, Joseph I.

AU - Jamerson, Kenneth

AU - Lyass, Asya

AU - Pencina, Karol

AU - Massaro, Joseph M.

AU - D’Agostino, Ralph B.

AU - Cutlip, Donald E.

AU - Murphy, Timothy P.

AU - Cooper, Christopher J.

N1 - Funding Information: The authors appreciate the support and encouragement provided by Diane M. Reid (Medical Officer, Division of Cardiovascular Sciences, National Heart, Lung and Blood Institute [NHLBI], Bethesda, MD). The Cardiovascular Outcomes in Renal Artery Stenosis Clinical Trial was supported by NHLBI of the National Institutes of Health grants U01HL071556, U01HL072734, U01HL072735, U01HL072736, and U01HL072737. Study drugs were provided by Astra Zeneca and Pfizer Inc. Study devices were provided by Cordis Corporation, and supplemental financial support was granted by both Cordis Corporation and Pfizer Inc. None of the sponsors had roles in design andconduct of the study; collection, management, analysis, and interpretation of the data; or review or approval of the manuscript. The content of this paper is solely the responsibility of the authors. Publisher Copyright: © 2016 by the American Society of Nephrology.

PY - 2016

Y1 - 2016

N2 - Background and objectives Atherosclerotic renal artery stenosis may cause kidney function loss, but effects of stenting on eGFR and clinical events associated with CKD are uncertain. Our study objectives were to determine effects of stenting on eGFR and predictors of clinical events. Design, setting, participants, & measurements: Participants (n=931) in the Cardiovascular Outcomes in Renal Artery Stenosis Trial (fromMay of 2005 to September of 2012) had >60% atherosclerotic renal artery stenosis and systolic hypertension on two or more antihypertensive drugs and/or stage >3 CKD. The intervention was stenting versus no stenting on a background of risk factor management: renin-angiotensin system inhibition, statin, antiplatelet therapy, and smoking cessation education. The effect of stenting on eGFR by the serum creatinine-cystatin C Chronic Kidney Disease Epidemiology Collaboration equation was the prespecified analysis of kidney function. Predictors of eGFR and CKD outcomes (>30% eGFR loss, ESRD, and death) and cardiovascular disease outcomes (stroke, myocardial infarction, heart failure, and death) controlling for eGFR and albuminuria were also determined. Results: eGFR was 59±24 ml/min per 1.73 m2 (mean±SD) at baseline. Over 3 years, eGFR change, assessed by generalized estimating equations, was-1.5±7.0ml/min per 1.73m2 per year in the stent group versus-2.3±6.3 ml/min per 1.73 m2 per year in the medical therapy only group (P=0.18). eGFR predictors (multiple variable generalized estimating equations) were age, albuminuria, systolic BP, and diabetes (inverse associations) as well as men, total cholesterol, andHDL cholesterol (positive associations). CKDoutcomes events occurred in 19%(175 of 931), and predictors (Cox proportional hazards models) included albuminuria (positive association), systolic BP (positive association), and HDL cholesterol (inverse association). Cardiovascular disease outcomes events occurred in 22% (207 of 931), and predictors included age, albuminuria, total cholesterol, prior cardiovascular disease, and bilateral atherosclerotic renal artery stenosis (positive associations). Conclusions: Stenting did not influence eGFR in participants with atherosclerotic renal artery stenosis receiving renin-angiotensin system inhibition-based therapy. Predictors of clinical events were traditional risk factors for CKD and cardiovascular disease.

AB - Background and objectives Atherosclerotic renal artery stenosis may cause kidney function loss, but effects of stenting on eGFR and clinical events associated with CKD are uncertain. Our study objectives were to determine effects of stenting on eGFR and predictors of clinical events. Design, setting, participants, & measurements: Participants (n=931) in the Cardiovascular Outcomes in Renal Artery Stenosis Trial (fromMay of 2005 to September of 2012) had >60% atherosclerotic renal artery stenosis and systolic hypertension on two or more antihypertensive drugs and/or stage >3 CKD. The intervention was stenting versus no stenting on a background of risk factor management: renin-angiotensin system inhibition, statin, antiplatelet therapy, and smoking cessation education. The effect of stenting on eGFR by the serum creatinine-cystatin C Chronic Kidney Disease Epidemiology Collaboration equation was the prespecified analysis of kidney function. Predictors of eGFR and CKD outcomes (>30% eGFR loss, ESRD, and death) and cardiovascular disease outcomes (stroke, myocardial infarction, heart failure, and death) controlling for eGFR and albuminuria were also determined. Results: eGFR was 59±24 ml/min per 1.73 m2 (mean±SD) at baseline. Over 3 years, eGFR change, assessed by generalized estimating equations, was-1.5±7.0ml/min per 1.73m2 per year in the stent group versus-2.3±6.3 ml/min per 1.73 m2 per year in the medical therapy only group (P=0.18). eGFR predictors (multiple variable generalized estimating equations) were age, albuminuria, systolic BP, and diabetes (inverse associations) as well as men, total cholesterol, andHDL cholesterol (positive associations). CKDoutcomes events occurred in 19%(175 of 931), and predictors (Cox proportional hazards models) included albuminuria (positive association), systolic BP (positive association), and HDL cholesterol (inverse association). Cardiovascular disease outcomes events occurred in 22% (207 of 931), and predictors included age, albuminuria, total cholesterol, prior cardiovascular disease, and bilateral atherosclerotic renal artery stenosis (positive associations). Conclusions: Stenting did not influence eGFR in participants with atherosclerotic renal artery stenosis receiving renin-angiotensin system inhibition-based therapy. Predictors of clinical events were traditional risk factors for CKD and cardiovascular disease.

KW - Albuminuria

KW - Blood pressure

KW - Cardiovascular disease

KW - Chronic kidney disease

KW - Glomerular filtration rate

KW - Hypertension

KW - Renal Artery Obstruction

KW - Renin angiotensin system

KW - Stents

UR - http://www.scopus.com/inward/record.url?scp=85009281201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009281201&partnerID=8YFLogxK

U2 - 10.2215/CJN.10491015

DO - 10.2215/CJN.10491015

M3 - Article

C2 - 27225988

AN - SCOPUS:85009281201

SN - 1555-9041

VL - 11

SP - 1180

EP - 1188

JO - Clinical Journal of the American Society of Nephrology

JF - Clinical Journal of the American Society of Nephrology

IS - 7

ER -

Effects of stenting for atherosclerotic renal artery stenosis on eGFR and predictors of clinical events in the CORAL trial

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this